GlaxoSmithKline (GSK – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Graham Parry from ...

Jefferies analyst Peter Welford maintained a Hold rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £14.50. The ...

We recently published a list of 12 Undervalued Defensive Stocks for 2025. In this article, we are going to take a look at ...

MHRA’s independence also questioned during Commons debate, with regulator accused of being too close to companies it ...

The announcement that CMC Motors Group will be shutting down has rekindled concerns about the state of Kenya’s business ...

Ischemic stroke market Insights: Rising prevalence of ischemic strokes boosts demand for effective treatment and prevention strategies.

Kassa and others said Big Pharma continues to invest even as private equity funds have pulled back. He noted ...

MUMBAI: Kedaara Capital  is laying it on  thick with advisors. The latest to be added on its roster is Jai Shankar Krishnan as an operating advisor, effective immediately.  With over three decades of ...

GSK PLC GSK shares inched down 0.37% to £13.54 Monday, on what proved to be an all-around favorable trading session for the ...

European Commission approves GSK’s Jemperli plus chemotherapy to treat patients with primary advanced or recurrent endometrial cancer: London, UK Tuesday, January 21, 2025, 09:0 ...

European regulators have expanded the usage of GSK's Jemperli drug for endometrial cancer, the pharmaceutical firm announced ...

Cancer treatment is undergoing a revolution, and immunotherapy is leading the charge. Unlike traditional methods like ...